Sermorelin cost: what it is, and what we will not pretend to know
What we evaluated: publicly advertised pricing for Sermorelin across telehealth and longevity providers
Date verified: July 12, 2026
Direct answer: We do not publish a price for Sermorelin, because we have not verified one. Telehealth and longevity clinics advertise widely varying figures, and we have not captured and dated them against provider sources under our pricing-verification methodology. Publishing an unverified number would be worse than publishing none.
Necessary qualification: we label an unverified price as unverified rather than publishing a plausible-looking number
Method: every figure is a total ongoing monthly cost (medication + any required membership), derived by plan total ÷ plan months. See our pricing-verification methodology.
How Sermorelin differs from the alternatives
Sermorelin versus tesamorelin — the distinction that matters most. They are both GHRH analogues and they are often sold interchangeably. They are not interchangeable on the one axis that counts: tesamorelin is FDA-approved (as Egrifta, for HIV-associated lipodystrophy). Sermorelin is not. Sermorelin was approved, as Geref, but that product was discontinued; FDA determined in 2013 that it was not withdrawn for reasons of safety or effectiveness. Sermorelin sold today is a compounded preparation.
So when a clinic offers you 'a GHRH peptide', ask which one and what its regulatory status is. If the answer is sermorelin, you are buying a compounded version of a drug that no longer has an approved product on the U.S. market. That may still be a reasonable choice with a good clinician — but you should make it knowingly.
The cost picture
Publishing an unverified number would be worse than publishing none. When we have captured them, they will appear here with a source and a verification date, exactly like our GLP-1 pricing.
| Field | Status |
|---|---|
| Advertised price | Evaluation in progress Verification pending — we have not captured it |
| Membership / consultation fees | Evaluation in progress Not publicly disclosed in a form we can verify |
| FDA status | Verified See our Sermorelin evidence page |
| Human clinical evidence | Verified Reviewed and graded on the Sermorelin page |
| Safety profile | Verified Reviewed on the Sermorelin page |
What we can tell you is what the evidence supports, what the FDA has and has not approved, and what questions to ask before you pay anyone anything. That is on the Sermorelin page, and it matters more than a price.
Before you consider price, consider evidence
What to ask before paying anyone
- What specific outcome are we targeting, and how will we measure whether it worked?
- What is the human evidence for that outcome — not the mechanism, the outcome?
- Is this compounded? By which state-licensed pharmacy?
- What is the total cost including consultation, follow-up and any required labs?
- What happens if it does not work — is there a point at which we stop?
Frequently asked questions
What does Sermorelin cost?
We have not verified a market price. On October 15, 2026, NexLife’s sermorelin injection page showed a regular price of $130.00 and was marked sold out, and Oak Longevity showed sermorelin pricing only after a free assessment. Ask any provider for the total monthly cost, including consultations and supplies, in writing.
Is Sermorelin FDA-approved?
No approved sermorelin product is on the U.S. market as of October 15, 2026. Its approved product, Geref, was discontinued, and FDA determined in 2013 that it was not withdrawn for safety or effectiveness reasons. Sermorelin is in none of FDA’s interim 503A compounding categories.
Why publish a cost page with no cost?
Because the most useful thing we can tell you about this treatment's price is that nobody has verified it — and that the evidence for the treatment itself is weaker than the marketing implies.
Sources
- U.S. Food and Drug Administration — approved labels and compounding guidance.
- PubMed / NIH — indexed human clinical literature.
- Our pricing-verification methodology and source policy.